In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC)

By Durai Malarvizhi  

Cancer Immunology, Immunotherapy, Vol. 58, Iss. 2, 2009-02 ,pp. : 209-220

Springer Publishing Company

Access to resources Recommend Favorite

In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line

By Santegoets Saskia   Schreurs Marco   Masterson Allan   Liu Ying   Goletz Steffen   Baumeister Hans   Kueter Esther   Lougheed Sinéad   Eertwegh Alfons   Scheper Rik   Hooijberg Erik   Gruijl Tanja  

Cancer Immunology, Immunotherapy, Vol. 55, Iss. 12, 2006-12 ,pp. : 1480-1490

Springer Publishing Company

Access to resources Recommend Favorite

A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes

By Larrieu Pierre   Ouisse Laure-Hélène   Guilloux Yannick   Jotereau Francine   Fonteneau Jean-François  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 10, 2007-10 ,pp. : 1565-1575

Springer Publishing Company

Access to resources Recommend Favorite

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination

By Romero Pedro   Cerottini Jean-Charles   Speiser Daniel  

Cancer Immunology, Immunotherapy, Vol. 53, Iss. 3, 2004-03 ,pp. : 249-255

Springer Publishing Company

Access to resources Recommend Favorite

Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes

By                                    

International Journal of Oncology, Vol. 40, Iss. 1, 2012-01 ,pp. : 63-70

Spandidos Publications

Access to resources Recommend Favorite